{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:23:05Z","timestamp":1787898185684,"version":"build-2784847793"},"reference-count":49,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&amp; D Program of China","award":["2016YFC1000900"],"award-info":[{"award-number":["2016YFC1000900"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2017-I2M-1-010"],"award-info":[{"award-number":["2017-I2M-1-010"]}]},{"name":"National Science and Technology Major Project of China","award":["2017zx09101001003"],"award-info":[{"award-number":["2017zx09101001003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Drug combinations have been the hotspot of the pharmaceutical industry, but the promising applications are limited by the unmet solubility and low bioavailability. In this work, novel cocrystals, consisting of two antithrombotic drugs with poor solubility and low bioavailability in vivo, namely, apixaban (Apx) and quercetin (Que), were developed to discover a potential method to improve the poor solubility and internal absorption of the drug combination. Compared with Apx, the dissolution behavior of Apx\u2013Que (1:1) and Apx\u2013Que\u20132ACN (1:1:2) was enhanced significantly, while the physical mixture of the chemicals failed to exhibit the advantages. The dissolution improvements of Apx\u2013Que\u20132ACN could be explained by the fact that the solid dispersion-like structure and column-shaped cage of Que accelerated the access of the solvent to the inner layer of Apx. The fracture of the hydrogen bonds of Apx, which was the joint of the adjacent Que chains, facilitated the break-up of the structures. Besides, the bioavailability of Apx\u2013Que was increased compared with the physical mixture and Apx, and Apx\u2013Que remained stable in high temperature and illumination conditions. Therefore, a drug\u2013drug cocrystal of two antithrombotic agents with poor solubility was developed, which exhibited greatly improved solubility, bioavailability and superior stability, indicating a novel method to overcome the shortages of drug combination.<\/jats:p>","DOI":"10.3390\/molecules26092677","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T22:51:42Z","timestamp":1620255102000},"page":"2677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Cocrystal of Apixaban\u2013Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs"],"prefix":"10.3390","volume":"26","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[{"name":"Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewen","family":"Kong","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingtai","family":"Jiao","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junke","family":"Song","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-4126","authenticated-orcid":false,"given":"Dezhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiguang","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Du","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12325-018-0675-3","article-title":"Effectiveness of a Fixed-Dose, Single-Pill Combination of Perindopril and Amlodipine in Patients with Hypertension: A Non-Interventional Study","volume":"35","author":"Fleig","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5301\/JN.2011.6271","article-title":"Role of the fixed-dose combination lercanidipine-enalapril in renal protection","volume":"24","author":"Egan","year":"2011","journal-title":"J. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40262-018-0654-5","article-title":"Drug\u2013Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir\/Sofosbuvir","volume":"57","author":"German","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/S0140-6736(14)60614-0","article-title":"Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: A randomised, multicentre study","volume":"383","author":"Giles","year":"2014","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003495-200767010-00007","article-title":"Fixed-dose combination lercanidipine\/enalapril","volume":"67","author":"Hair","year":"2007","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","article-title":"Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection","volume":"313","author":"Poordad","year":"2015","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(10)60322-4","article-title":"Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: A randomised non-inferiority trial","volume":"375","author":"Tshefu","year":"2010","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejps.2018.04.024","article-title":"Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions","volume":"119","author":"Nadvorny","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1570163054866864","article-title":"Artificial Neural Networks to Optimize Formulation Components of a Fixed- Dose Combination of Rifampicin, Isoniazid and Pyrazinamide in a Microemulsion","volume":"2","author":"Glass","year":"2005","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1208\/s12248-012-9378-x","article-title":"Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products","volume":"14","author":"Mitra","year":"2012","journal-title":"AAPS J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5173(01)00831-6","article-title":"Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation","volume":"228","author":"Shishoo","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0378-5173(01)00754-2","article-title":"A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem","volume":"228","author":"Singh","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejpb.2012.11.027","article-title":"New formulation approaches to improve solubility and drug release from fixed dose combinations: Case examples pioglitazone\/glimepiride and ezetimibe\/simvastatin","volume":"84","author":"Taupitz","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1021\/cg9001187","article-title":"Understanding and Predicting the Effect of Cocrystal Components and pH on Cocrystal Solubility","volume":"9","author":"Bethune","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"ref_17","first-page":"418","article-title":"The role of solvent in mechanochemical and sonochemical cocrystal formation: A solubility-based approach for predicting cocrystallisation outcome","volume":"11","author":"Childs","year":"2008","journal-title":"CrystEngComm"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1021\/acs.cgd.8b01911","article-title":"Improving Compliance and Decreasing Drug Accumulation of Diethylstilbestrol through Cocrystallization","volume":"19","author":"Li","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1002\/jps.21341","article-title":"Ethyl-paraben and nicotinamide mixtures: Apparent solubility, thermal behavior and X-ray structure of the 1:1 co-crystal","volume":"97","author":"Nicoli","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1021\/acs.cgd.6b00639","article-title":"Drug\u2013Drug Multicomponent Crystals as an Effective Technique to Overcome Weaknesses in Parent Drugs","volume":"16","author":"Putra","year":"2016","journal-title":"Cryst. Growth Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1021\/acs.cgd.8b00696","article-title":"Novel Salt Cocrystal of Chrysin with Berberine: Preparation, Characterization, and Oral Bioavailability","volume":"18","author":"Sa","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1021\/acs.cgd.6b01848","article-title":"Co-crystal of Tramadol Hydrochloride\u2013Celecoxib (ctc): A Novel API\u2013API Co-crystal for the Treatment of Pain","volume":"17","author":"Almansa","year":"2017","journal-title":"Cryst. Growth Des."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40268-018-0235-y","article-title":"Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial","volume":"18","author":"Videla","year":"2018","journal-title":"Drugs R&D"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1021\/acs.cgd.9b00008","article-title":"Differential Solution Behavior of the New API\u2013API Co-Crystal of Tramadol\u2013Celecoxib (CTC) versus Its Constituents and Their Combination","volume":"19","author":"Port","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bcp.13428","article-title":"Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: Findings from a four-way randomized open-label phase I clinical trial","volume":"84","author":"Videla","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"New Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans","volume":"37","author":"Raghavan","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","first-page":"382","article-title":"Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: Structure-activity relationships","volume":"12","author":"Beretz","year":"1982","journal-title":"Inflamm. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1016\/0006-2952(82)90581-0","article-title":"Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin","volume":"31","author":"Beretz","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.3892\/mmr.2017.7781","article-title":"Synthesis of regioselectively acylated quercetin analogues with improved antiplatelet activity","volume":"16","author":"Duan","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1079\/BJN20061831","article-title":"Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: A pilot study","volume":"96","author":"Hubbard","year":"2006","journal-title":"Br. J. Nutr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nutres.2005.04.004","article-title":"Effects of \u03b1-tocopherol, l-arginine, and quercetin on aggregation of human platelets","volume":"25","author":"Kobzar","year":"2005","journal-title":"Nutr. Res."},{"key":"ref_35","first-page":"1","article-title":"Dual Roles of Quercetin in Platelets: Phosphoinositide-3-Kinase and MAP Kinases Inhibition, and cAMP-Dependent Vasodilator-Stimulated Phosphoprotein Stimulation","volume":"2012","author":"Oh","year":"2012","journal-title":"Evidence-Based Complement. Altern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.cgd.6b00266","article-title":"Improving the Solubility and Bioavailability of Apixaban via Apixaban\u2013Oxalic Acid Cocrystal","volume":"16","author":"Chen","year":"2016","journal-title":"Cryst. Growth Des."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105216","DOI":"10.1016\/j.ejps.2020.105216","article-title":"A new cocrystal of isoniazid-quercetin with hepatoprotective effect: The design, structure, and in vitro\/in vivo performance evaluation","volume":"144","author":"Liu","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"128865","DOI":"10.1016\/j.molstruc.2020.128865","article-title":"Salt solvates of quinolones and oxicams: Theoretical computation, structural characterization and dissolution studies","volume":"1223","author":"Jiao","year":"2021","journal-title":"J. Mol. Struct."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1107\/S2053229618016911","article-title":"An acetonitrile-solvated cocrystal of piroxicam and succinic acid with co-existing zwitterionic and non-ionized piroxicam molecules","volume":"75","author":"Liu","year":"2019","journal-title":"Acta Crystallogr. Sect. C Struct. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.compositesa.2019.02.024","article-title":"Enhanced breakdown strength of aligned-sodium-titanate- nanowire\/epoxy nanocomposites and their anisotropic dielectric properties","volume":"120","author":"Chen","year":"2019","journal-title":"Compos. Part. A: Appl. Sci. Manuf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123662","DOI":"10.1016\/j.cej.2019.123662","article-title":"Asymmetric alicyclic amine-polyether amine molecular chain structure for improved energy storage density of high-temperature crosslinked polymer capacitor","volume":"387","author":"Chen","year":"2020","journal-title":"Chem. Eng. J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cui, J., Zhou, Z., Jia, M., Chen, X., Shi, C., Zhao, N., and Guo, X. (2020). Solid Polymer Electrolytes with Flexible Framework of SiO2 Nanofibers for Highly Safe Solid Lithium Batteries. Polymers, 12.","DOI":"10.3390\/polym12061324"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.compositesb.2018.07.019","article-title":"Enhanced through-plane thermal conductivity of PTFE composites with hybrid fillers of hexagonal boron nitride platelets and aluminum nitride particles","volume":"153","author":"Pan","year":"2018","journal-title":"Compos. Part. B: Eng."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijheatmasstransfer.2017.12.015","article-title":"Investigation of the through-plane thermal conductivity of polymer composites with in-plane oriented hexagonal boron nitride","volume":"120","author":"Pan","year":"2018","journal-title":"Int. J. Heat Mass Transf."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1049\/hve.2017.0056","article-title":"Thermal conductivity and dielectric properties of bismaleimide\/cyanate ester copolymer","volume":"2","author":"Wan","year":"2017","journal-title":"High. Volt."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"105422","DOI":"10.1016\/j.ejps.2020.105422","article-title":"The role of pH and dose\/solubility ratio on cocrystal dissolution, drug supersaturation and precipitation","volume":"152","author":"Machado","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/acs.cgd.8b00362","article-title":"Tadalafil\u2013malonic acid cocrystal: Physicochemical characterization, pH-solubility, and supersaturation studies","volume":"18","author":"Shimpi","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1021\/acs.cgd.9b00541","article-title":"Hepatoprotective Cocrystals of Isoniazid: Synthesis, Solid State Characterization, and Hepatotoxicity Studies","volume":"19","author":"Yadav","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.apsb.2018.09.008","article-title":"The effects of pH, surfactant, ion concentration, coformer, and molecular arrangement on the solubility behavior of myricetin cocrystals","volume":"9","author":"Ren","year":"2019","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/9\/2677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:56:53Z","timestamp":1760162213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/9\/2677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["molecules26092677"],"URL":"https:\/\/doi.org\/10.3390\/molecules26092677","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]}}}